Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan in children with recessive dystrophic epidermolysis bullosa
2015-003670-32Phase 2Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of losartan in Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by Universitätsklinikum Freiburg. Primary endpoint: Occurrence of a serious safety concern. Started Apr 2016; status: completed.
02
Drugs
losartan
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on 2015-003670-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003670-32.